Advanced Search
Click Traffic
  • Number of total visits : 4084314
  • Number of visits today : 1665
  • Number of users online :0
  • Number of downloads :1509030
Peter A McCullough

Peter A Mccullough, MD, MPH., FACC, FACP, FCCP, FAHA

Consultant Cardiologist and Chief Academic and Scientific Officer, St. John Providence Health System, Providence Hospital and Medical Center, Providence Park Heart Institute, Novi, MI, USA

After receiving a bachelor’s degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate of the University of Texas Southwestern Medical School in Dallas.  He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship at William Beaumont Hospital, and master’s degree in public health at the University of Michigan.

Over the past 14 years, Dr. McCullough served as the Program Director in Cardiovascular Diseases at Henry Ford Health System, Chief of Cardiology at the University of Missouri-Kansas City School of Medicine, and Chief of Nutrition and Preventive Medicine at William Beaumont Hospital.  Within the seven-hospital St. John Providence Health System, Dr. McCullough oversees graduate medical education and research.  In addition, Dr. McCullough leads a clinical and research team fostering innovative approaches to cardiorenal syndromes.  He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 800 published, scientific communications.  He is the author of the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook.  Dr. McCullough is the current Chair of the National Kidney Foundation’s Kidney Early Evaluation Program, the largest community screening effort for chronic diseases in the U.S.  He is the co-editor of Reviews in Cardiovascular Medicine and serves on the editorial boards of multiple specialty journals.  He has led numerous clinical trial steering, data safety monitoring, and events committees and has testified before the U.S. Food and Drug Administration and the U.S. Congressional Oversight Panel.